In this episode, we’re joined by Daniel O’Connor, Director of Regulatory Policy and Early Access at The Association of the British Pharmaceutical Industry. Daniel previously spent almost 18 years at the Medicines and Healthcare products Regulatory Agency (MHRA) and over his career has specialized in improving and incentivizing pathways to rare disease treatment development.

Join Patrick and Daniel as they discuss orphan drug designation, the importance of international collaboration, and how unlocking new regulatory approaches to preventative medicine can help change the future of rare and ultra-rare conditions.